S
Soufflé Therapeutics Stock
HealthTechLooking to sell Soufflé Therapeutics stock or options?
Founded: 2022Funding to Date: $330.8M
Developer of a targeted gene therapy intended to treat autoimmune diseases and cardiac diseases. The company develops a platform for targeted, tissue-specific genetic therapy delivery through the discovery of new cell proteins and pathways that can deliver genetic payloads, enabling healthcare professionals to target macrophages and cardiac cells for the treatment of autoimmune diseases and cardiac diseases.
Notable investors include:
Other investors include:
Polaris Partners, Vida Ventures (Los Angeles), Safar Partners.